Hudson Bay Capital Management LP Acquires New Holdings in Alignment Healthcare, Inc. $ALHC

Hudson Bay Capital Management LP bought a new stake in Alignment Healthcare, Inc. (NASDAQ:ALHC) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 262,500 shares of the company’s stock, valued at approximately $4,581,000. Hudson Bay Capital Management LP owned approximately 0.13% of Alignment Healthcare at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Teacher Retirement System of Texas boosted its holdings in shares of Alignment Healthcare by 85.8% during the 3rd quarter. Teacher Retirement System of Texas now owns 102,827 shares of the company’s stock valued at $1,794,000 after acquiring an additional 47,472 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Alignment Healthcare in the 3rd quarter worth about $3,499,000. Inspire Investing LLC bought a new position in Alignment Healthcare in the third quarter valued at about $1,129,000. Cinctive Capital Management LP bought a new position in Alignment Healthcare in the third quarter valued at about $3,814,000. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Alignment Healthcare by 32.9% during the second quarter. Ameritas Investment Partners Inc. now owns 13,031 shares of the company’s stock valued at $182,000 after purchasing an additional 3,225 shares in the last quarter. Institutional investors own 86.19% of the company’s stock.

Insiders Place Their Bets

In other Alignment Healthcare news, insider Hyong Kim sold 18,404 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $17.84, for a total value of $328,327.36. Following the transaction, the insider directly owned 367,701 shares of the company’s stock, valued at approximately $6,559,785.84. The trade was a 4.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Sebastian Burzacchi sold 15,361 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $17.84, for a total value of $274,040.24. Following the transaction, the chief operating officer owned 258,630 shares in the company, valued at $4,613,959.20. The trade was a 5.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,300,393 shares of company stock valued at $44,411,027 in the last 90 days. Company insiders own 7.00% of the company’s stock.

Alignment Healthcare Price Performance

ALHC stock opened at $17.34 on Friday. The company has a quick ratio of 1.71, a current ratio of 1.71 and a debt-to-equity ratio of 1.80. The firm has a market cap of $3.54 billion, a price-to-earnings ratio of -1,732.27, a PEG ratio of 2.54 and a beta of 1.18. The company’s fifty day simple moving average is $20.44 and its 200 day simple moving average is $18.80. Alignment Healthcare, Inc. has a 12-month low of $11.63 and a 12-month high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.10. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The business’s quarterly revenue was up 44.4% on a year-over-year basis. During the same period last year, the company posted ($0.16) EPS. On average, analysts expect that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on ALHC. UBS Group upped their price objective on Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, January 14th. JPMorgan Chase & Co. lifted their target price on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Robert W. Baird set a $28.00 target price on shares of Alignment Healthcare in a report on Friday, January 30th. Wall Street Zen cut shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, KeyCorp reiterated an “overweight” rating and set a $28.00 price target on shares of Alignment Healthcare in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alignment Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $24.56.

More Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Strong fundamentals — Alignment reported Q4 revenue of ~$1.01B and an EPS beat (‑$0.05 vs. consensus ‑$0.15) with revenue up ~44% YoY, which supports longer‑term growth expectations. Earnings Summary
• Positive Sentiment: Analyst bullishness — Multiple brokerages have raised price targets and maintain Buy/Overweight views (e.g., TD Cowen, JPMorgan, KeyCorp, Robert W. Baird), leaving a consensus analyst stance that is constructive for the stock. Analyst Coverage
• Neutral Sentiment: Short‑interest data published for March appears erroneous (shows 0 shares / NaN changes). Do not treat those figures as evidence of new short pressure until exchanges correct the data.
• Neutral Sentiment: High institutional ownership (~86%) can mute volatility from retail flows but also means institutional positioning matters for future moves; a Zacks comparison piece contrasts ALHC with peers for valuation context. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Secondary offering announced by a major shareholder — the planned secondary raises potential near‑term selling supply and is a clear negative for price action until the offering size and timing are known. Alignment Healthcare announces secondary offering by major shareholder
• Negative Sentiment: Clustered insider selling — several senior executives reported sales on Mar 18–19 (CEO John E. Kao: 73,046 shares; President Dawn Maroney: 36,749; COO Sebastian Burzacchi: 15,361; plus multiple other officers, and Robert Scavo sold 11,285). These simultaneous disposals (~tens of thousands of shares each at ~$17.84) create headline risk and likely contributed to today’s negative sentiment. Representative SEC filings: Kao — Kao SEC Filing, Scavo — Scavo SEC Filing

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.